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Abst rac t  
 
Clinical studies of large human populations and pharmacological interventions in rodent 
models have recently suggested that anti-hypertensive drugs that target angiotensin II 
(Ang II) activity may also improve loss of bone mineral density. Here we identified in a 
genetic screen the Ang II type I receptor (AT1R) as a potential determinant of 
osteogenic differentiation and, implicitly, bone formation. Silencing of AT1R expression 
by RNA interference severely impaired the maturation of a multipotent mesenchymal 
cell line (W20-17) along the osteoblastic lineage. The same effect was also observed 
after the addition of the AT1R antagonist losartan but not the AT2R inhibitor PD123,319. 
Additional cell culture assays traced the time of greatest losartan action to the early 
stages of W20-17 differentiation, namely during cell proliferation. Indeed, addition of 
Ang II increased proliferation of differentiating W20-17 and primary mesenchymal stem 
cells and this stimulation was reversed by losartan treatment. Cells treated with losartan 
also displayed an appreciable decrease of activated (phosphorylated)-Smad2/3 
proteins. Moreover, Ang II treatment elevated endogenous transforming growth factor β 
(TGFβ) expression considerably and in an AT1R-dependent manner. Finally, 
exogenous TGFβ was able to restore high proliferative activity to W20-17 cells that were 
treated with both Ang II and losartan. Collectively, these results suggest a novel 
mechanism of Ang II action in bone metabolism that is mediated by TGFβ and targets 
proliferation of osteoblast progenitors. This article is protected by copyright. All rights 
reserved 
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In t roduc t ion  
 
Genetic and environmental factors are implicated in the onset and progression of 
hypertension and osteopenia/osteoporosis, two major age-related diseases that are an 
increasing healthcare burden in industrialized countries. Different degrees of low bone 
mineral density (BMD) characterize disease progression from the largely asymptomatic 
osteopenia to the increased risk for fractures in osteoporosis (NIH Consensus 
Development Panel on Osteoporosis Prevention, 2001). Low BMD reflects the 
imbalance between bone formation by osteoblasts and bone resorption by osteoclasts 
during physiological bone remodeling. This homeostatic process involves a large 
number of systemic signals that are produced by different organ systems, such as 
parathyroid hormone, blood calcium and leptin, as well as local signals that are secreted 
by cells or released from the extracellular matrix (ECM), such as chemokines and 
transforming growth factor β (TGF) signaling molecules (Karsenty, 2006; Kitahara et 
al., 2003; Ono et al., 2007). Equally complex is the clinical presentation of hypertension 
in which dysregulation of the renin-angiotensin system (RAS) contributes greatly to 
disease progression. RAS normally regulates water fluid balance and blood pressure by 
promoting renin-induced production of angiotensin II (Ang II) both systemically and 
locally in several tissues, including bone (Daniels et al., 2007; Izu et al., 2009). Indeed, 
a number of clinical studies have suggested a potential association between 
hypertension and BMD and between the latter and stroke in selected cohorts of patients 
(Dennis et al., 2002; Kanis et al., 2001; von der Recke et al., 1999). Furthermore, Lynn 
et al. have recently reported higher than normal BMD in elderly individuals who had 
been treated with angiotensin-converting enzyme (ACE) inhibitors (Lynn et al., 2006). 
These observations have, therefore, raised the intriguing possibility that anti-
hypertensive drugs may also reduce bone loss. Unfortunately, progress in this direction 
has been hampered by our limited understanding of RAS activity in the skeleton and by 
controversial findings of RAS action in rodent models of bone loss. 
Ang II signals through receptors 1 and 2 (AT1R and AT2R, respectively) to activate G 
protein and non-G protein-related transduction pathways with a myriad of highly 
contextual cellular outcomes. For example, whereas AT1R antagonism prevents 
experimentally induced abdominal aortic aneurysm, AT2R blockade accelerates it 
(Lucarini et al., 2009). In spite of the aforementioned clinical evidence, the role of Ang II 
signaling in bone metabolism remains controversial with reports of both positive and 
negative results (Broulik et al., 2001; Gu et al., 2012; Izu et al., 2009; Shimizu et al., 
2009). On the one hand, the angiotensin receptor blocker (ARB) olmesartan has been 
shown to attenuate bone loss in ovariectomized hypertensive rats and to inhibit Ang II 
stimulation of receptor activator of nuclear factor κ-B ligand (RANKL) production in 
cultured osteoblasts (Shimizu et al., 2008). Moreover, the systemic administration of the 
ARB blocker telmisartan has been proven effective in improving bone callus formation 
and fracture healing in mice (Zhao et al., 2014). On the other hand, no changes in 
baseline bone density have been noted in rodents systemically treated with the ARB 
losartan, and pharmacological or genetic inactivation of AT2R was found to increase 
bone mass in mice (Broulik et al., 2001). Additionally, earlier cell culture experiments 
have indicated that Ang II treatment inhibits the maturation of primary calvaria 
osteoblasts, which represent a highly heterogenous population of cells at different 
stages of differentiation (Hagiwara et al., 1998). More recently, it has been shown that 
Ang II administration induces mitochondrial alterations and apoptosis in the same 
cellular system (Li et al., 2014). 
Blockade of AT1R activity has also been shown to lower promiscuous TGF signaling in 
experimental renal and cardiac fibrosis, and in mouse models of and in patients afflicted 
with Marfan syndrome (MFS), (Brooke et al., 2008; Cohn et al., 2007; Habashi et al., 
2006). MFS is a congenital disease of the connective tissue that is caused by mutations 
in the ECM protein fibrillin-1 and that includes osteopenia as part of the phenotype 
(Ramirez and Dietz, 2007b). MFS mutations impair tissue integrity by interfering with the 
formation and/or stability of fibrillin-1 assemblies (microfibrils) as well as with the ability 
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of microfibrils to sequester and store latent TGF complexes and bone morphogenetic 
proteins (BMPs) in the ECM (Ramirez and Dietz, 2007a; Nistala et al., 2010a). Relevant 
to bone formation and remodeling, TGF is a key local regulator of osteogenic 
differentiation that promotes recruitment and proliferation of progenitor osteoblasts and 
inhibits differentiation of committed pre-osteoblasts (Roelen and Dijke, 2003). In this 
respect, locally released TGF signals are believed to participate in controlling the 
overall rate of bone formation by balancing the pool of mesenchymal progenitors that 
are committed to the osteoblast lineage and the pool of committed osteoblasts that are 
primed to undergo terminal differentiation (Nistala et al., 2010a). It follows that the 
effects of RAS activity on TGF signaling may be different depending on whether they 
are examined in cell cultures that represent mesenchymal progenitors or committed 
osteoblasts, as it was the case in the previous report of Ang II inhibition of calvarial 
osteoblast maturation. 
The present study describes the characterization of AT1R as one of the gene products 
that drives osteogenic differentiation, in part, through the activation of TGF signaling in 
mesenchymal progenitor cells. AT1R identification was based on a high-throughput 
screening protocol that employed the expression of a small hairpin RNA (shRNA)-
containing library in a multipotent murine cell line (W20-17) induced to differentiate into 
osteoblasts and that used mineral nodule formation as an informative read-out of in vivo 
bone formation. The results of our cell culture experiments are consistent with the 
notion that Ang II stimulates TGFβ production and progenitor osteoblast proliferation 
through the activity of AT1R. These findings shed new light on the controversial role of 
RAS activity in bone mass maintenance and implicitly, on the potential benefit of using 
anti-hypertensive drugs to improve low BMD in individuals afflicted with 
osteopenia/osteoporosis.  
 
mate r ia ls  and  methods  
 
W20-17 culture conditions  
W20-17 cell line was purchased from American Type Culture Collection (ATCC/LGC 
standards, Milan, Italy). Primary murine mesenchymal stem cells (mMSCs) were 
isolated from C57Bl/6 mice’s bone marrow as described previously (Esposito et al., 
2009). Human mesenchymal stem cells (hMSCs) were isolated from bone marrow of 
healthy adult donors after informed consent (Mariotti et al.,2008). mMSCs and W20-17 
cells were seeded at a density of 6,000 cells/cm2 and cultured in regular medium 
consisting of D-MEM (Euroclone, Siziano, Italy) supplemented with 10% fetal bovine 
serum (HyClone, Northumberland, UK) and 4 mM L-glutamine (Gibco, Paisley, UK) in 
absence of antibiotics. hMSCs were seeded at a density of 5,000 cells/cm2 and cultured 
in regular medium consisting of D-MEM supplemented with 20% fetal bovine serum and 
4 mM L-glutamine in absence of antibiotics. For osteoblastic differentiation induction, 
cells were cultured in D-MEM with 10% fetal bovine serum, 4 mM L-glutamine, 0.05 mM 
ascorbic acid 2-phosphate (Sigma, St. Louis, MO US), 10 mM glycerol 2-phosphate 
(Sigma, St. Louis, MO US), 10-6 M dexamethasone (Sigma, St. Louis, MO US). Cells 
were grown to 70%-90% confluence and then cultured in osteogenic medium for 21 
days. 
Alizarin red and alkaline phosphatase staining  
For alizarin red staining, W20-17 cells were washed with PBS and fixed in 10% 
formaldehyde (Sigma-Aldrich, St. Louis, MO) for 1 hour; after rinsing with distilled water, 
they were incubated with 2% alizarin red S (Sigma-Aldrich, St. Louis, MO) at pH 4.1 for 
10 minutes. Excess staining was removed using water (Digirolamo et al., 1999). After 
visual examination, the mineralized deposit-bound dye was extracted adding 100 µl of 4 
M guanidine–hydrochloric acid (Sigma-Aldrich, St. Louis, MO) and incubating them over 
night at room temperature. A semi-quantitative assay was used to determine the 
amount of cell-bound dye assessing absorbance at 490 nm of a 10-times dilution of the 
resulting supernatant. For alkaline phosphatase (AP) staining, cells were washed after 
14 days of osteogenic differentiation with PBS and fixed in 10% cold neutral formalin 
buffer (10% formalin, 0.1M Na2HPO4, 0.029M NaH2PO4, Sigma-Aldrich, St. Louis, MO). 
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Cells were then rinsed with distilled water and stained with a substrate solution 
containing 0.24 mM naphthol AS MX-PO4 (Sigma-Aldrich, St. Louis, MO), 0.4% N,N-
dimethylformamide (Sigma-Aldrich, St. Louis, MO), 1.6 μM red violet LB salt (Sigma-
Aldrich, St. Louis, MO S) in 0.2 M Tris-HCl pH 8.3 (Carlo Erba Reagenti, Milano, Italy) 
for 45 minutes at room temperature. Excess staining was removed washing twice with 
distilled water and AP-positive cells visualized under microscope. Determination of AP 
activity was performed as previously described (Bruder et al., 1997). Briefly, cells were 
washed twice with Tyrode's balanced salt solution (50 mM Tris-HCl pH 7.4, 0.15 M 
NaCl) and then incubated with 5 mM p-nitrophenylphosphate (Sigma-Aldrich, St. Louis, 
MO) in 50 mM glycine (Sigma-Aldrich, St. Louis, MO US), 1 mM MgCl2 (Carlo Erba 
Reagenti, Milano, Italy), pH 10.5 at 37°C for 15 minutes. The reaction was stopped with 
3 M NaOH (Carlo Erba Reagenti, Milano, Italy). Relative activity was determined 
measuring absorbance at 405 nm. 
shRNA -med ia ted  sc reen ing  
W20-17 cells were plated in 96-well plates at a density of 8,000 cells/cm2 . 
Transfections of the different shRNA-expressing plasmids (Open Biosystem, Huntsville, 
AL) were performed using 0.2 µl of Lipofectamine 2000 (Invitrogen, Paisley, UK) with 
200 ng of plasmid, according to manufacturer’s instructions. Transfected cells were 
enriched with a 2 µg/ml puromycin selection in regular medium (Sigma, St. Louis, MO) 
for 3 days, then cultured in differentiation medium for 21 days, as previously described. 
Cells were stained with alizarin red to identify shRNAs that were able to interfere with 
the differentiation process. Wells completely or partially stained with alizarin red were 
scored as differentiated, whereas those not stained were considered positive and the 
relevant genes were further analyzed as potentially relevant for osteoblast 
differentiation. 
Rea l - t ime  PCR quan t i ta t ion  o f  os teob las t  d i f f e ren t ia t i on  
marke rs  
Total RNA was extracted from W20-17 cultured in control or differentiation media at 
different time points using TriReagent (Sigma-Aldrich, St. Louis, MO) and then treated 
with DNase I (Ambion, Monza, Italy). Reverse transcription polymerase chain reaction 
(RT-PCR) was performed with M-MuLV Reverse Transcriptase (New England BioLabs, 
Beverly, MA) using 2 µg of total RNA with 5 µm random primers. Real time PCR was 
performed using the SYBR Green PCR master mixture in an ABI PRISM 7500 
apparatus (Applera, Foster City, CA). Levels of target genes were quantified using 
specific oligonucleotide primers and normalized for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression. 
Ang io tens in  I I  s igna l ing b lockade  
Angiotensin II (Sigma, St. Louis, MO), PD123,319 (Sigma, St. Louis, MO) and losartan 
potassium (Fluka, St. Louis, MO) were added to the medium every day during 
differentiation protocols as described for each different experiment in the Results 
section. 
P ro l i f e ra t ion  assays   
Cells were seeded in 96-well plates and cultured for 4 days in osteogenic medium. Cells 
were then washed with PBS and cultured for 48 hours as described in the Results 
section. For rescue experiments, 5 or 10 ng/ml of human recombinant TGF1 (Sigma, 
St. Louis, MO) were added to the medium 1 hour after losartan treatment. Proliferation 
was determined with CellTiter 96 AQueous Non-Radioactive assay (Promega, Madison, 
WI) measuring absorbance at 490 nm, according to manufacturer’s instructions. 
W este rn  b lo t  assays   
Cells were treated with lysis buffer (1mM EDTA, 70 mM NaCl, 1% Triton X-100, 50 mM 
Tris-HCl, pH 7.5), in presence of proteinase inhibitors (Complete Protease Inhibitor 
Cocktail, Roche) and phosphatase inhibitors (5 mM sodium fluoride and 1mM sodium 
orthovanadate). Proteins were quantified using Bradford solution (AppliChem, 
Darmstadt, Germany). Protein extracts were run on 10% SDS-PAGE gels, transferred 
on Immuno-Blot PVDF membranes (Bio-Rad, Segrate, Italy). Western blots were 
performed with the following antibodies: Phospho (p)Smad2/3 (monoclonal, Cell 
Signaling, Danvers, MA US), Smad2/3 (monoclonal, Cell Signaling, Danvers, MA), 
 This article is protected by copyright. All rights reserved 
 
pSmad1/5/8 (polyclonal, Cell Signaling, Danvers, MA US), Smad1 (polyclonal, Cell 
Signaling, Danvers, MA), AT1R (polyclonal, Santa Cruz, Heidelberg, Germany), 
GAPDH (monoclonal, Santa Cruz, Heidelberg, Germany) and secondary anti-mouse or 
anti-rabbit horseradish peroxidase-conjugated antibodies (Amersham Bioscience, 
Uppsala, Sweden). Detection was performed by chemiluminescence, according to 
manufacturer’s protocols (ECL plus, GE Healthcare). Results were quantitated using 
Chemidoc (Biorad, Hercules, CA, USA), according to manufacturer's instructions.  
Statistical analysis 
Data are expressed as mean values ± standard deviation of 3 independent 
experiments. Two-tailed Student’s t test was performed using GraphPad Prism 5.0 
software (San Diego, CA, USA). A P-value <0.05 was considered statistically significant. 
 
Resu l t s  
 
shRNA -med ia ted  iden t i f i ca t ion  o f  AT1R as  a  regu la to r  
o f  os teob las t  d i f f eren t ia t ion  
We have previously transfected mouse embryonic stem cells with a library of shRNA-
expressing plasmids in order to identify genes that confer stemness (Parisi et al., 2008). 
The same library, that consists of 66,600 shRNAs covering the entire murine 
transcriptome, was used in the present study to identify genes involved in osteoblast 
differentiation. Briefly, until now 10,000 independent shRNAs were stably transfected in 
cells with features of immature mesenchymal progenitors (W20-17 cell line) under 
previously established conditions that ensure chromosomal integration of shRNA 
plasmids. Puromycin-resistant cell clones were then scored for the inability of forming 
mineral nodules 18-21 days after the addition of osteogenic medium compared to cells 
transfected with non-silencing shRNA used as controls (Fig. 1, panel A). Parallel W20-
17 cells transfected with plasmids expressing shRNAs for known determinants of 
osteoblastogenesis, such as BMP1 and Smad5, served as reference cultures of failed 
ECM mineralization (Fig. 1, panels B and C). Such a screening protocol identified 650 
shRNA-transfected cell clones that displayed a substantial paucity of mineralized 
nodules. The 650 shRNAs corresponded to 208 genes with unknown role at the time of 
the screening and to 442 known genes, which Gene Ontology segregated into 5 
functionally separate groups (Fig. 1, panel D). A partial list representative of the different 
functional categories of candidate genes identified during the screening is reported in 
Suppl. Table 1. The present report focuses on the characterization of the gene encoding 
for AT1R; characterization of other genes potentially implicated in osteogenic 
differentiation will be described elsewhere along with additional details of the shRNA 
screen.  
Following AT1R identification by the shRNA screening, we confirmed the relevance of 
this gene for proper osteoblast maturation with an additional silencing experiment with 
an independent shRNA against a different sequence of AT1R (Fig. 2). This conclusion 
was independently validated by the finding that losartan, a specific AT1R antagonist, 
reduced alizarin red staining of W20-17 cultures nearly to the same extent as AT1R 
silencing (Fig. 3, panels A through E). As expected, losartan treatment also brought 
down to base-line levels the AP activity of osteoinduced W20-17 cultures (Fig. 3, panel 
F). Furthermore, quantitative Real-time PCR (qPCR) revealed that AT1R is expressed 
earlier and at a higher level than AT2R, suggesting a possible involvement of the former 
gene product in the early stages of osteoblast differentiation (Fig. 3, panel G). In 
addition, we observed that ATR1 shRNA-mediated interference reduced RunX2 and AP 
levels during differentiation (Suppl. Fig. 1). Incidentally, treatment of W20-17 cultures 
with the AT2R inhibitor PD123,319 had virtually no effect on ECM mineralization, thus 
excluding a prominent role of this Ang II receptor in the differentiation process of 
osteoblast progenitors (Fig. 3, panels A through E).  
AT1R s igna l ing  i s  most l y  requ i red  fo r  p re -os teob las t  
p ro l i f e ra t ion  
The next set of experiments was designed to interrogate the stage in which AT1R 
activity is most relevant for the progression of W20-17 cell differentiation. Accordingly, 
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W20-17 cells were first treated with losartan or PD123,319 at the time of (day 0) or 7 or 
14 days after addition of osteogenic medium and scored for mineral nodule formation at 
day 21 of differentiation (Fig. 4). This assay correlated most of the inhibitory activity of 
losartan on osteoblast maturation with the first week of cell culture when differentiating 
W20-17 cells are in the proliferative phase (Fig. 4, panel A-C and Suppl Fig. 2). 
Consistent with the above data (Fig. 3), PD123,319 treatment had no effect on W20-17 
maturation, irrespective of the time of administration of the AT2R inhibitor (Fig. 4, panels 
D-F). In the second assay, cell proliferation was measured in osteoinduced or untreated 
W20-17 cells cultured in the presence of increasing Ang II concentrations. Unlike cells 
grown in regular medium, those cultured in osteogenic medium displayed a dose-
dependent increase in proliferative activity in response to Ang II treatment (Fig. 5, panel 
A). Importantly, losartan (but not PD123,319) completely abrogated Ang II-induced 
stimulation of W20-17 cell proliferation (Fig. 5, panel B). Ang II treatment also stimulated 
proliferation of primary mMSCs, albeit to a minor extent compared to W20-17 cells; 
increase in proliferation was reversed by losartan also in mMSCs, thus further 
implicating the hormone and the AT1R receptor in the physiological regulation of bone 
formation (Fig. 5, panel B). 
AT1R inh ib i t i on  b locks  SMAD -med ia ted  induc t ion  o f  
p ro l i f e ra t ion  
TGFβ promotes proliferation of osteoblast progenitors and AT1R stimulates canonical 
TGFβ signaling in several cell types (Urano et al., 1999; Chon RD et al., 2007; Zhang et 
al., 2014). Therefore, we evaluated whether losartan inhibition of W20-17 cell 
proliferation was associated with a reduction of TGFβ signaling in these cells. Western 
blot analyses revealed a significant decrease in the relative ratio of pSmad2/3 to 
Smad2/3 in losartan-treated compared to untreated cells (Fig. 6, panels A and B). By 
contrast, no differences were noted in the relative ratio of pSmad1/5/8 to Smad1, which 
transduce BMP signals (Fig. 6, panels A and C). Taken at face value, these results 
suggested specificity of losartan inhibition of canonical TGFβ signaling. In accordance 
with recent evidence suggesting that Ang II stimulates TGFβ expression (Li and Zhuo, 
2008), qPCR analyses revealed a substantial increase of TGFβ transcript levels in W20-
17 cells cultured in osteogenic medium or in regular medium supplemented with Ang II 
(Fig. 6, panel D); in addition, osteogenic medium induced also a stimulation of 
Angiotensinogen expression, thus showing the presence of an autocrine loop and 
further corroborating Ang II relevance in this developmental process (Suppl Fig. 3). In 
both cases, TGFβ up-regulation was blunted by the addition of losartan, further 
confirming the causal relationship between Ang II and TGFβ signaling in these cells 
(Fig. 6, panel D). Moreover, addition of TGFβ to W20-17 cells cultured in presence of 
both Ang II and losartan restored cell proliferation to the same level as in cultures with 
only Ang II (Fig. 6, panel E). Lastly, we confirmed a decrease in pSmad2/3 
accumulation in mMSCs cultured for 4 days in the presence of losartan; this observation 
further reiterates the physiological significance of our findings (Fig. 6, panels A-C). 
Collectively, these results were interpreted to indicate that Ang II stimulates TGFβ 
production and osteoblast progenitors proliferation through the activity of AT1R. This 
conclusion is consistent with the well-established role of TGFβ signaling in promoting 
proliferation of progenitor but not differentiated osteoblasts (Erlebacher and Derynck, 
1996; Urano et al., 1999). Importantly, we were able to confirm these findings also in 
hMSCs. Indeed, losartan, but not PD123,319, completely abrogated Ang II-induced 
stimulation of proliferation of hMSCs pre-treated with osteogenic medium, whereas the 
addition of TGFβ counteracted losartan inhibitory effect and restored cell proliferation 
(Suppl Fig. 4). These findings show that, as in mouse, Ang II stimulates proliferation of 
osteoprogenitor cells even in human; this effect is AT1R-mediated and occurs, at least 
in part, through the activation of TGFβ pathway. 
 
D iscuss ion  
In spite of suggestive clinical evidence and experimental data, RAS role in bone mass 
maintenance remains ill defined and, consequently, the potential benefits of anti-
hypertensive drug therapies in osteopenia/osteoporosis have yet to be demonstrated. 
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The present study identified AT1R as one of the gene products that drive osteoblast 
differentiation, in part, through the stimulation of TGFβ production, which in turn 
participates in promoting progenitor cell proliferation. This conclusion was based on the 
findings that At1r gene silencing by shRNA or AT1R antagonism by losartan similarly 
impair maturation of multipotent W20-17 cells that are induced to differentiate into 
osteoblasts, and that Ang II stimulates Tgfβ gene expression and W20-17 cell 
proliferation in an AT1R-dependent manner. While our results are consistent with an 
earlier report by Hiruma et al. (1997) that implicated Ang II in promoting calvarial 
osteoblast proliferation via AT1R (Hiruma et al., 1997), they are also at odd with the 
finding by Hagirwara et al. (1998) that the hormone decreases AP activity and mineral 
nodule formation in the same cell culture system (Hagiwara et al., 1998). We believe 
that these discrepancies may simply reflect contextual differences in Ang II action 
between cells that represent distinct stages of osteoblast differentiation and/or different 
populations of differentiating osteoblasts. We support our contention by noting that 
TGFβ signaling promotes proliferation of osteoprogenitor cells, which were used in our 
study, but inhibits proliferation of differentiated osteoblasts, which were used in the 
Hagiwara et al. investigations (Erlebacher and Derynck, 1996; Urano et al., 1999). 
Although relevant to the physiological condition, the analysis of Ang II impact on W20-
17 cell differentiation was limited to the anabolic arm of bone remodeling without taking 
into account other important aspects operating in vivo. Among other factors, bone 
remodeling is driven by local coupling between the opposing activities of osteoblasts 
and osteoclasts, as well as by osteoblast regulation of osteoclast differentiation and 
activity through the production of positive (M-CSF and RANKL) and negative 
(osteoprotegerin) osteogenic factors. RAS regulation of bone homeostasis is similarly 
complex. Shimuzu et al. have shown that ACE inhibitors can block BMD decrease in 
ovariectomized spontaneously hypertensive rats by attenuating osteoclast activity 
(Shimizu et al., 2009). In a separate study, other investigators have concluded that Ang 
II promotes bone loss by increasing osteoblast production of RANKL through AT1R-
mediated induction of the mitogen-activated protein kinases (MAPKs) (Asaba et al., 
2009). There is also genetic evidence for a functional interaction between the two Ang II 
receptors with regard to osteoblast-supported osteoclastogenesis through RANKL 
production (Asaba et al., 2009). Ongoing investigations are examining how Ang II and 
cognate receptors influences the expression of pro- and anti-osteoclastogenic factors in 
our cell model of progenitor osteoblasts. Recent data have in fact demonstrated that 
Ang II-mediated activation of AT1R regulates osteoclast differentiation in vitro as well as 
in mice developing skeleton. The authors have shown that losartan administration 
increases bone mass and impairs osteoclastogenesis both in vivo and in a cellular 
model through the suppression of RANKL-mediated activation of MAPK pathway (Chen 
et al., submitted). 
Moreover, it has recently been shown that Ang II could affect bone mass homeostasis 
also by regulating ECM turnover in osteoid by osteoblasts. Indeed, Nakai et al. 
demonstrated that Ang II administration was able to induce the production of matrix 
metalloproteinases (MMPs) -3 and -13 in ROS17/2.8 rat osteosarcoma cell line; this 
effect seems to be AT1R-mediated since losartan but not PD123,319 completely 
abrogated Ang II-induced MMPs expression (Nakai et al., 2013). 
Pharmacological interventions both in cell cultures and rodents have recently connected 
AT1R activity with the stimulation of the canonical TGFβ signaling and ECM production. 
Accordingly, AT1R antagonism has been used in animal models as well as in patients 
with fibrotic conditions driven in part by TGFβ signaling, such as scleroderma 
(Kawaguchi et al., 2004), or with congenital abnormalities associated with improper 
TGFβ activation, such as aortic aneurysm in MFS (Brooke et al., 2008; Habashi et al., 
2006). Our findings are consistent with these data in that they indicate that Ang II is a 
positive regulator of TGFβ production in osteoblasts. The following lines of evidence 
support this contention; (a) Ang II enhances the accumulation of Tgfβ transcripts in 
undifferentiated W20-17 cells; (b) AT1R antagonism blunts Ang II enhancement of Tgfβ 
expression in undifferentiated W20-17 cells and Smad2/3 activation during cell 
differentiation of W20-7 cells as well as mMSCs; (c) both TGFβ and Ang II stimulate 
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W20-17 cells and hMSCs proliferation in an AT1R-dependent manner; and (d) TGFβ 
can restore high proliferative activity in W20-17 cells and hMSCs treated with both Ang 
II and losartan. Based on these findings, it is therefore conceivable that ARB strategies 
might prove effective not only in normalizing aortic aneurysm but also osteopenia in 
MFS. However, Nistala et al. have shown that losartan administration was able to 
ameliorate aortic wall degeneration but not bone loss in a mouse model of MFS (Nistala 
et al., 2010b). This result could be due to the complex interplay between TGFβ and 
other local or systemic regulators of bone homeostasis that may be altered in MFS, 
such as the BMPs normally sequestered and store by fibrillin-1 assemblies in the ECM. 
Moreover, another possible explanation could be associated to the mouse model 
employed in the study and the pathogenic mechanism underlying osteopenia. Indeed, in 
the fibrillin-1 mutant mice (Fbn1mgR/mgR) used by Nistala et al., osteoblasts develop 
normally but stimulate osteoclast activity in vitro more than control cells, suggesting a 
probable alteration in bone resorption rather than in bone formation. On the other end, 
in the tight skin (Tsk/+) mouse model of MFS, osteopenia seems to be correlated to a 
reduced rate of osteoblast maturation and, therefore, losartan treatment could be 
beneficial.  In fact, while ARBs and ACE inhibitors represent promising new means to 
manage age-related osteopenia/osteoporosis, pharmacologic inhibition of AT1R 
signaling may also have unexpected consequences on BMD depending on the 
pathogenetic mechanism underlying disease progression. Decreased osteoblast 
proliferation may reduce RANKL-mediated stimulation of osteoclast proliferation with the 
net effect of normalizing bone metabolism. ARB therapy could also prove beneficial in 
diseases due to hyperproliferation of mesenchymal stem cells or progenitor osteoblasts. 
By contrast, ARBs may exacerbate bone loss in conditions in which there is an 
osteoblast-independent increase in bone resorption or characterized by an impaired 
osteoblast maturation.  
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Figure 1. shRNA-mediated silencing allows identification of genes involved in 
osteoblastogenesis. W20-17 cells transfected with shRNAs interfering with control 
(scrambled) shRNA are able to differentiate into osteoblasts and produce mineralized 
deposits (panel A); on the other hand, cells transfected with shRNAs interfering with 
BMP1 (panel B) or SMAD5 (panel C), genes known to be relevant for 
osteoblastogenesis, are unable to produce mineralized nodules. Scale bar corresponds 
to 100 µm. Genes that, when interfered, produced absence of mineral deposits were 
classified for their ontology; most of the genes were of unknown function whereas a 
significant proportion were involved in signal transduction (panel D). AT1R belongs to 
the “signal transduction / G-protein-coupled receptor protein signaling pathway” group. 
 
Figure 2. Silencing of AT1R gene reduces osteoblast-mediated calcium deposition after 
21 days of differentiation. Cells transfected with shAT1r(1) (panel A) and shAT1r(2) 
(panel B) show absence of alizarin red staining whereas untransfected cells (panel C) 
and cells transfected with a non silencing shRNA (panel D) show mineral deposits. 
Scale bar corresponds to 100 µm. Microscopy data are confirmed by alizarin red dye 
quantification (panel E): differences in mineral deposition between cells where AT1R 
had been silenced and controls are highly significant (**p<0.01). Effective silencing of 
AT1R has been confirmed in W20-17 cells transfected with shAT1r(1) or shAT1r(2) that 
show absence of the protein product after western blot analysis with specific antibodies. 
GAPDH levels were included as loading control (panel F). 
 
Figure 3. Pharmacological inhibition of AT1R reduces osteoblast-mediated calcium 
deposition after 21 days of differentiation. W20-17 cells treated with osteogenic medium 
(panel A) and the AT2R inhibitor PD 123,319 (panel C) show mineral deposits whereas 
cells treated with osteogenic medium and losartan show a significant reduction 
(*p<0.05) of alizarin red staining (panel B); untreated cells do not show a significant 
presence of mineral deposition (panel D). Scale bar corresponds to 100 µm. Microscopy 
data were confirmed by alizarin red dye quantification: cells treated with osteogenic 
medium and losartan or with regular medium showed a significant decrease in the 
absorbance at 490 nm (*p<0.05 and **p<0.01, respectively) compared to cells treated 
with osteogenic medium (panel E, results are reported as fold change compared to cells 
treated with osteogenic medium alone). Losartan-treated cells reduced also AP activity 
after 14 days of treatment with osteogenic medium (panel F, results are reported as fold 
change compared to cells treated with osteogenic medium alone). Expression of AT1R 
in the first days of differentiation (black bars) is compatible with a relevance of this gene 
in the early stages of differentiation; lower levels and delayed expression of AT2R 
(white bars) are compatible with a function of this gene in differentiated osteoblast 
(panel G, results are reported as ATR/GAPDH levels ratio). 
 
Figure 4. Inhibition of AT1R in the early days of differentiation is able to reduce 
osteoblast-mediated calcium deposition after 21 days of differentiation. W20-17 cells 
were kept in osteogenic medium and stained after 21 days of differentiation. Losartan 
and PD 123,319 were added to the medium starting from day 0 (panel A and D, 
respectively), from day 7 (panel B and E) and from day 14 (panel C and F). Staining of 
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control W20-17 cells differentiated in osteogenic medium with no addition is shown in 
panel G. Scale bar corresponds to 100 µm. Only cells treated with losartan from day 0 
(panel A) show reduction of alizarin red staining. Ratio of alizarin red absorbance in the 
treated cells versus control cells is reported in panel H: only cells treated with losartan 
from day 0 show a significant (**p<0.01) alteration of this ratio confirming the previous 
observations. 
 
Figure 5. Ang II-mediated stimulation of AT1R is required for proliferation of W20-17 
cells treated with osteogenic medium. Addition of Ang II to W20-17 prestimulated with 
osteogenic medium significantly (**p<0.01) increases proliferation in a dose-dependent 
(*p<0.05 and **p<0.01) fashion (panel A, black bars); naïve W20-17 cells show minimal 
increase of proliferation (panel A, white bars). Ang II-mediated stimulation of 
proliferation (*p<0.05) in differentiating W20-17 (black bars) and primary bone marrow 
mMSCs (white bars) is inhibited by losartan-mediated AT1R pharmacological blockade 
as well as by AT1R shRNA whereas PD123,319-mediated inhibition of AT2R has no 
effect (panel B). 
 
Figure 6. Pharmacological inhibition of AT1R reduces SMAD2/3 phosphorylation 
through inhibition of TGFβ transcription. W20-17 cells treated with osteogenic medium 
(Control) show increase of phosphorylation of SMAD2/3, usually activated by TGFβ 
signaling, at the early time-points of differentiation and absence of pSMAD2/3 at the end 
of the mineralization process, whereas cells treated with osteogenic medium and 
losartan do not show an increase of SMAD2/3 phosphorylation (panel A); data were 
confirmed in differentiating primary mMSCs after 4 days of treatment (C: control cells 
and L: cells treated with losartan). Levels of pSMAD1/5/8 are not significantly modified 
in losartan-treated W20-17 and mMSC cells (panel A). GAPDH levels were included as 
loading control (panel A). Ratio between pSMAD2/3 and SMAD2/3 (panel B) and 
pSMAD1/5/8 and SMAD1 (panel C) were obtained after quantitation of the relative 
signals at the different time-points; the black and white bars refer to control and 
losartan-treated cells, respectively (panel B and C). Treatments with either osteogenic 
medium or Ang II induce a significant increase of TGFβ mRNA levels (*p<0.001) that in 
both cases is reversed by losartan (panel D, results are reported as TGFβ/GAPDH 
expression levels ratio); in addition, losartan-mediated inhibition of proliferation of cells 
treated with osteogenic medium or Ang II is counteracted by the addition of TGFβ in the 
medium (*p<0.05 and **p<0.01) (panel E). 
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